Literature DB >> 15350940

The Virginia Mason approach to localized pancreatic cancer.

Vincent J Picozzi1, L William Traverso.   

Abstract

This article describes the approaches presently employed at Virginia Mason Medical Center for treatment of localized pancreatic cancer, including preoperative staging, operative intervention, incorporation of adjuvant therapy, and supportive care.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350940     DOI: 10.1016/j.soc.2004.06.002

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  11 in total

1.  Detection of disseminated pancreatic cells by amplification of cytokeratin-19 with quantitative RT-PCR in blood, bone marrow and peritoneal lavage of pancreatic carcinoma patients.

Authors:  Katrin Hoffmann; Christiane Kerner; Wolfgang Wilfert; Marc Mueller; Joachim Thiery; Johann Hauss; Helmut Witzigmann
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 2.  Development of pancreatoduodenectomy in North America.

Authors:  Thomas Schnelldorfer; Kaye Reid-Lombardo; Michael G Sarr
Journal:  Surg Today       Date:  2011-03-02       Impact factor: 2.549

Review 3.  The Development of Oncolytic Adenovirus Therapy in the Past and Future - For the Case of Pancreatic Cancer

Authors:  Mizuho Sato-Dahlman; Masato Yamamoto
Journal:  Curr Cancer Drug Targets       Date:  2018       Impact factor: 3.428

4.  5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer.

Authors:  David P Eisenberg; Prasad S Adusumilli; Karen J Hendershott; Zhenkun Yu; Michael Mullerad; Mei-Ki Chan; Ting-Chao Chou; Yuman Fong
Journal:  J Gastrointest Surg       Date:  2005-11       Impact factor: 3.452

Review 5.  Adjuvant therapy in pancreatic cancer: a critical appraisal.

Authors:  Helmut Oettle; Peter Neuhaus
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer.

Authors:  Reza F Saidi; Stephen G Remine; Michael J Jacobs
Journal:  HPB (Oxford)       Date:  2007       Impact factor: 3.647

7.  Effect of Flt3 ligand gene transfer in experimental pancreatic cancer.

Authors:  E Ryschich; G Huszty; N Wentzensen; E Schmidt; H P Knaebel; J Encke; A Märten; M W Büchler; J Schmidt
Journal:  Int J Colorectal Dis       Date:  2006-03-10       Impact factor: 2.571

Review 8.  [The role of radiation therapy in treatment of pancreatic cancer from the viewpoint of radio-oncologists].

Authors:  C Timke; J P Debus
Journal:  Radiologe       Date:  2009-02       Impact factor: 0.635

Review 9.  Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].

Authors:  Katrin Hoffmann; Angela Marten; Katja Lindel; Stefan Fritz; Dirk Jager; Markus W Buchler; Jan Schmidt
Journal:  BMC Cancer       Date:  2006-05-10       Impact factor: 4.430

10.  Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].

Authors:  H P Knaebel; A Märten; J Schmidt; K Hoffmann; C Seiler; K Lindel; H Schmitz-Winnenthal; S Fritz; T Herrmann; H Goldschmidt; R Krempien; U Mansmann; J Debus; V Diehl; M W Büchler
Journal:  BMC Cancer       Date:  2005-04-12       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.